PPARδ activation reduces insulin resistance by regulating mitochondrial oxidation capacity in skeletal muscle (25), and the glucose-insulin cycle, thus enhancing glucose utilization and reducing triacylglycerol deposition (26). The gene discussed is PPARD; the disease is Insulin resistance.